{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:25:00Z","timestamp":1770729900223,"version":"3.49.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019225","name":"Pediatric Transplantation and Cellular Therapy Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R13HL172559-01"],"award-info":[{"award-number":["1R13HL172559-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtct.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:18:32Z","timestamp":1734437912000},"page":"69.e1-69.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation"],"prefix":"10.1016","volume":"31","author":[{"given":"Neel S.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-8817","authenticated-orcid":false,"given":"Andrew C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-2276","authenticated-orcid":false,"given":"Lev","family":"Gorfinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Ibanez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-4740","authenticated-orcid":false,"given":"Eric R.","family":"Tkaczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-9972","authenticated-orcid":false,"given":"Sandra A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-4897","authenticated-orcid":false,"given":"Christine N.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-1113","authenticated-orcid":false,"given":"Seth J.","family":"Rotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-0714","authenticated-orcid":false,"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-8757","authenticated-orcid":false,"given":"Geoffrey D.E.","family":"Cuvelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.12.011_bib0001","article-title":"Current use and outcome of hematopoietic stem cell transplantation","author":"Bolon","year":"2022","journal-title":"CIBMTR Summary Slides"},{"key":"10.1016\/j.jtct.2024.12.011_bib0002","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.2019000216","article-title":"Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria","volume":"134","author":"Cuvelier","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0003","series-title":"Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 6.0","year":"2023"},{"key":"10.1016\/j.jtct.2024.12.011_bib0004","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2017.05.022","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bbmt.2017.04.026","volume":"23","author":"Heimall","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.bbmt.2018.04.002","article-title":"Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on late effects after pediatric HCT","volume":"24","author":"Shenoy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.seminhematol.2011.10.012","article-title":"Long-term follow-up and management guidelines in pediatric patients after allogenic hematopoietic stem cell transplantation","volume":"49","author":"Frangoul","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0008","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbmt.2016.01.023","article-title":"Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group Report","volume":"22","author":"Chow","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0009","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtct.2023.12.001","article-title":"International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: a 2023 update","volume":"30","author":"Rotz","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.024","article-title":"Late effects in pediatric allogeneic hematopoietic stem cell transplantation for nonmalignant diseases: proxy- and patient-reported outcomes","volume":"29","author":"Bense","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.10.012","article-title":"Long-term organ function after HCT for SCD: a report from the sickle cell transplant advocacy and research alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0012","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2016.03.001","article-title":"Survival after hematopoietic stem cell transplant in patients with dyskeratosis congenita: systematic review of the literature","volume":"22","author":"Barbaro","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.12.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.44015","article-title":"Deficit accumulation index and biological markers of aging in survivors of childhood cancer","volume":"6","author":"Williams","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2024.12.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101820","article-title":"Impact of iron overload in hematopoietic stem cell transplantation","volume":"78","author":"Wang","year":"2023","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0016","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","article-title":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial","volume":"36","author":"Eichinger","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.12.011_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.028","article-title":"Comparison of pulmonary toxicity after total body irradiation- and busulfan-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0018","doi-asserted-by":"crossref","first-page":"e13773","DOI":"10.1111\/petr.13773","article-title":"Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed","volume":"24","author":"Weinhard","year":"2020","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0019","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.bbmt.2016.05.024","article-title":"Late effects after umbilical cord blood transplantation in very young children after busulfan-based, myeloablative conditioning","volume":"22","author":"Allewelt","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.014","article-title":"Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy","volume":"28","author":"Lee","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0021","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a Task Force Report from the National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0022","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0023","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","article-title":"Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD","volume":"7","author":"Buxbaum","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.12.011_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtct.2021.02.035","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2020 Etiology and Prevention Working Group Report","volume":"27","author":"Williams","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0025","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.jtct.2024.12.011_bib0026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtct.2022.05.038","article-title":"Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 National Institutes of Health Consensus Project Task Force","volume":"28","author":"Cuvelier","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0027","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3389\/fimmu.2020.02017","article-title":"Autoimmunity following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Buxbaum","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0028","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0029","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2024.12.011_bib0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0031","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0033","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41409-022-01628-3","article-title":"Predictors and outcomes of flares in chronic graft-versus-host disease","volume":"57","author":"El Jurdi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0034","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.2022.281114","article-title":"Durable discontinuation of systemic therapy for chronic graft-versus-host disease: myth or reality?","volume":"108","author":"Pavletic","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.12.011_bib0036","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0037","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3324\/haematol.2021.279814","article-title":"Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.12.011_bib0038","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2008.07.015","article-title":"Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy","volume":"14","author":"Perez-Simon","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0039","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.bbmt.2017.08.005","article-title":"Predictors for permanent discontinuation of systemic immunosuppression in severely affected chronic graft-versus-host disease patients","volume":"23","author":"Curtis","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0040","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1182\/blood-2011-04-349068","article-title":"Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease","volume":"118","author":"Jacobsohn","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0041","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.bbmt.2015.07.025","article-title":"Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by National Institutes of Health Consensus Criteria after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Inagaki","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0042","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.bbmt.2014.06.030","article-title":"Immunologic resolution of human chronic graft-versus-host disease","volume":"20","author":"Mahadeo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0043","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3389\/fimmu.2018.01889","article-title":"Thymopoiesis in pre- and post-hematopoietic stem cell transplantation","volume":"9","author":"da Rocha","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0044","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1182\/blood-2011-02-334623","article-title":"Thymic T-cell development in allogeneic stem cell transplantation","volume":"117","author":"Krenger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bbmt.2004.12.001","article-title":"Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children","volume":"11","author":"Eyrich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0046","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-0039.2011.01820.x","article-title":"Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again","volume":"79","author":"Toubert","year":"2012","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jtct.2024.12.011_bib0047","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ajh.25717","article-title":"Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis","volume":"95","author":"Goklemez","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0048","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.bbmt.2011.04.002","article-title":"A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change","volume":"17","author":"Mitchell","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0049","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamadermatol.2018.5459","article-title":"Interrater reliability of clinical grading measures for cutaneous chronic graft-vs-host disease","volume":"155","author":"Cardones","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/bloodadvances.2019000918","article-title":"Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia","volume":"4","author":"Inamoto","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.12.011_bib0051","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.bbmt.2019.05.008","article-title":"Organ changes associated with provider-assessed responses in patients with chronic graft-versus-host disease","volume":"25","author":"Martin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0052","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0053","doi-asserted-by":"crossref","first-page":"eabg3083","DOI":"10.1126\/scitranslmed.abg3083","article-title":"Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures","volume":"14","author":"Dubouchet","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0054","first-page":"143","article-title":"Patient-reported treatment response in chronic graft-versus-host disease","volume":"109","author":"Im","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.12.011_bib0055","article-title":"Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods study","volume":"14","author":"Mitchell","year":"2023","journal-title":"Front Psychol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0056","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/bmt.2013.48","article-title":"Characteristics of chronic GVHD after cord blood transplantation","volume":"48","author":"Newell","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0057","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jtct.2021.05.030","article-title":"Methods to assess disease activity and severity in cutaneous chronic graft-versus-host disease: a critical literature review","volume":"27","author":"Shakshouk","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0058","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00403-023-02626-1","article-title":"Interrater reproducibility of the Myoton and durometer devices to quantify sclerotic chronic graft-versus-host disease","volume":"315","author":"Ghosh","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jtct.2024.12.011_bib0059","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41409-020-01158-w","article-title":"Longitudinal tracking of skin dynamic stiffness to quantify evolution of sclerosis in chronic graft-versus-host disease","volume":"56","author":"Baker","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0060","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.xjidi.2021.100037","article-title":"Optimal biomechanical parameters for measuring sclerotic chronic graft-versus-host disease","volume":"1","author":"Baker","year":"2021","journal-title":"JID Innov"},{"key":"10.1016\/j.jtct.2024.12.011_bib0061","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41409-018-0346-7","article-title":"Non-invasive measurement of sclerosis in cutaneous cGVHD patients with the handheld device Myoton: a cross-sectional study","volume":"54","author":"Chen","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0062","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1468-3083.2003.00516.x","article-title":"Chronic cutaneous sclerodermoid graft-versus-host disease: evaluation by 20-MHz sonography","volume":"17","author":"Gottlober","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0063","doi-asserted-by":"crossref","first-page":"adv00395","DOI":"10.2340\/00015555-3747","article-title":"Assessment of sclerodermoid chronic graft-versus-host disease with colour doppler ultrasound","volume":"101","author":"Giavedoni","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2020.11.023","article-title":"Optical coherence tomography for quantifying human cutaneous chronic graft-versus-host disease","volume":"27","author":"Chen","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/lsm.22788","article-title":"Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions","volume":"50","author":"Deegan","year":"2018","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0066","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00256-008-0535-3","article-title":"MR findings in patients with disabling musculocutaneous chronic graft-versus-host disease","volume":"37","author":"Horger","year":"2008","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0067","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archdermatol.2009.78","article-title":"Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease","volume":"145","author":"Clark","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0068","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2214\/AJR.08.1699","article-title":"Musculocutaneous chronic graft-versus-host disease: MRI follow-up of patients undergoing immunosuppressive therapy","volume":"192","author":"Horger","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0069","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/RLU.0b013e3182816559","article-title":"Imaging findings and therapy response monitoring in chronic sclerodermatous graft-versus-host disease: preliminary data of a simultaneous PET\/MRI approach","volume":"38","author":"Sauter","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0070","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0071","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report","volume":"21","author":"Carpenter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0072","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2012.09131.x","article-title":"Organ-specific management and supportive care in chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0073","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/curroncol31030108","article-title":"Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development","volume":"31","author":"Kim","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0074","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2011.10360.x","article-title":"German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD","volume":"165","author":"Marks","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0075","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbmt.2014.10.019","article-title":"Musculoskeletal, neurologic, and cardiopulmonary aspects of physical rehabilitation in patients with chronic graft-versus-host disease","volume":"21","author":"Smith","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0076","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.reuma.2022.12.002","article-title":"Chronic graft-versus-recipient disease: systematic review of joint and fascial involvement","volume":"19","author":"Hidalgo Calleja","year":"2023","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.jtct.2024.12.011_bib0077","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MRR.0000000000000275","article-title":"Are graft-versus-host-disease patients missing out on the vital occupational therapy services? A systematic review","volume":"41","author":"Bakhsh","year":"2018","journal-title":"Int J Rehabil Res"},{"key":"10.1016\/j.jtct.2024.12.011_bib0078","first-page":"851","article-title":"Therapeutic experience on multiple contractures in sclerodermoid chronic graft versus host disease","volume":"17","author":"Choi","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2024.12.011_bib0079","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/bmt.2017.155","article-title":"Is there any role for physical therapy in chronic GvHD?","volume":"53","author":"Mohammed","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0080","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2012.01.017","article-title":"Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"18","author":"Tran","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0081","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.apmr.2020.10.141","article-title":"Rehabilitation Interventions in the multidisciplinary management of patients with sclerotic graft-versus-host disease of the skin and fascia","volume":"102","author":"Moles-Poveda","year":"2021","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jtct.2024.12.011_bib0082","first-page":"445","article-title":"Rehabilitation of chronic graft versus host disease in children. A clinical series","volume":"43","author":"Carenzio","year":"2007","journal-title":"Eura Medicophys"},{"key":"10.1016\/j.jtct.2024.12.011_bib0083","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/j.bbmt.2020.08.004","article-title":"Challenging and practical aspects of nutrition in chronic graft-versus-host disease","volume":"26","author":"Pereira","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0084","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41409-020-0782-z","article-title":"Anxiety, depression, and mental health-related quality of life in survivors of pediatric allogeneic hematopoietic stem cell transplantation: a systematic review","volume":"55","author":"Di Giuseppe","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.01.016","article-title":"Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ruggeri","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0086","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.2023021336","article-title":"TCRalphabeta\/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis","volume":"143","author":"Merli","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0087","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0088","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1182\/bloodadvances.2021006885","article-title":"The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease","volume":"6","author":"Pang","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.12.011_bib0089","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12890-017-0466-7","article-title":"Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation","volume":"17","author":"Namkoong","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0090","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.rmed.2014.09.006","article-title":"Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Schlemmer","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0091","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1513\/AnnalsATS.202001-006OT","article-title":"Pulmonary complications of pediatric hematopoietic cell transplantation. A National Institutes of Health Workshop Summary","volume":"18","author":"Tamburro","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtct.2024.12.011_bib0092","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/TP.0b013e31829df2c0","article-title":"Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: unresolved questions","volume":"96","author":"Holm","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2024.12.011_bib0093","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11684-017-0538-3","article-title":"Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation","volume":"12","author":"Gao","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0094","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbmt.2014.04.008","article-title":"Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Cheng","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0095","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.bbmt.2017.08.025","article-title":"Recovery of pulmonary function after allogeneic hematopoietic cell transplantation in children is associated with improved survival","volume":"23","author":"Srinivasan","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0096","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.24897","article-title":"Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Inaba","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.12.011_bib0097","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0098","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0099","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0100","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0101","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.011_bib0102","article-title":"Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1\/2 iMAGINE study","volume":"28","author":"Carpenter","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40272-022-00543-w","article-title":"Ibrutinib: pediatric first approval","volume":"25","author":"Keam","year":"2023","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jtct.2024.12.011_bib0104","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2352-3026(24)00174-1","article-title":"Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study","volume":"11","author":"Locatelli","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0105","unstructured":"Health NIo. Inclusion across the lifespan. 2019."},{"key":"10.1016\/j.jtct.2024.12.011_bib0106","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0108","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jtct.2021.03.029","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report","volume":"27","author":"Pidala","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2011.254","article-title":"Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity","volume":"26","author":"Grkovic","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.12.011_bib0111","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.011_bib0112","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/bmt.2013.95","article-title":"Active thrombopoiesis is associated with worse severity and activity of chronic GVHD","volume":"48","author":"Bat","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3892\/mco.2013.192","article-title":"Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome","volume":"2","author":"Beier","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0114","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/bmt.2014.194","article-title":"Nail dystrophy, edema, and eosinophilia: harbingers of severe chronic GVHD of the skin in children","volume":"49","author":"Huang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.017","article-title":"Characterization of hepatic dysfunction in subjects diagnosed with chronic GVHD by NIH consensus criteria","volume":"28","author":"Yang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0116","article-title":"High levels of FVIII and Von Willebrand factor in chronic graft-versus-host disease","volume":"54","author":"Pulanic","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0117","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/ejh.13531","article-title":"Prolactin, a potential biomarker for chronic GVHD activity","volume":"106","author":"Salas","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0118","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1703711","article-title":"Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation","volume":"30","author":"Couriel","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11926-021-00996-x","article-title":"Clinical characteristics of myositis associated with graft-versus-host disease","volume":"23","author":"Limaye","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jtct.2024.12.011_bib0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bmt.2008.297","article-title":"Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT","volume":"43","author":"Oda","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.12.011_bib0121","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/mus.27214","article-title":"Immune-mediated neuromuscular complications of graft-versus-host disease","volume":"63","author":"Saw","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jtct.2024.12.011_bib0122","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/jnen\/nlz111","article-title":"Chronic graft versus host myopathies: noninflammatory, multi-tissue pathology with glycosylation disorders","volume":"79","author":"Pestronk","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jtct.2024.12.011_bib0123","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14764172.2019.1710537","article-title":"Fractional CO(2) laser for the treatment of sclerodermatous cGVHD","volume":"22","author":"Labadie","year":"2020","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.jtct.2024.12.011_bib0124","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pde.15146","article-title":"Atopic dermatitis-like graft-versus-host disease treated with dupilumab","volume":"40","author":"Larijani","year":"2023","journal-title":"Pediatr Dermatol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:03:29Z","timestamp":1769915009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724008121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666636724008121"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}